Back to results
US 11,111,315 B2Granted
Heterodimeric antibodies that bind CD3 and tumor antigens
AssigneeXencor, Inc.
InventorsMatthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel heterodimeric antibodies.
Claims11
A composition comprising an CD123 antigen binding domain comprising:
- a) a variable heavy domain comprising a vhCDR1 having SEQ ID NO:440, vhCDR2 having SEQ ID NO:441 and a vhCDR3 having SEQ ID NO:442;
- and
- b) a variable light domain comprising a v1CDR1 having SEQ ID NO:444, v1CDR2 having SEQ ID NO:445 and a v1CDR3 having SEQ ID NO:446.
A heterodimeric antibody comprising:
- a) a first monomer comprising:
- i) a first IgG Fc domain;
- and
- ii) a single chain variable fragment comprising a first variable heavy chain, a first variable light chain, and a linker that attaches said first variable heavy chain with said first variable light chain;
- b) a second monomer comprising:
- i) a VH-CH1-hinge-CH2-CH3 monomer, wherein VH is a second variable heavy chain comprising a vhCDR1 having SEQ ID NO:440, vhCDR2 having SEQ ID NO:441 and a vhCDR3 having SEQ ID NO:442, and CH2-CH3 is a second IgG Fc domain;
- and
- c) a light chain comprising a second variable light chain comprising a v1CDR1 having SEQ ID NO:444, v1CDR2 having SEQ ID NO:445 and a v1CDR3 having SEQ ID NO:446,
- wherein said second variable heavy chain and said second variable light chain form a CD123 binding domain.
6 more elements
Dependencies are inferred from the claim text.